Related Experiment Video

Updated: Apr 28, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.5K

Bruton's TK inhibitors: structural insights and evolution of clinical candidates

Li Xing1, Adrian Huang

  • 1Biotherapeutics Chemistry, Pfizer Inc, 200 Cambridgepark Drive, Cambridge, MA 02140, USA.

Future Medicinal Chemistry
|June 5, 2014
PubMed

Insights

Bruton

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • Bruton's Tyrosine Kinase (BTK) is a key target for treating inflammatory diseases and B-cell malignancies.
  • Understanding BTK's structure and function is crucial for developing targeted therapies.
  • The kinase domain's flexibility allows for the design of potent and selective inhibitors.

Purpose of the Study:

  • To review the development of Bruton's Tyrosine Kinase (BTK) inhibitors.
  • To highlight the therapeutic potential of BTK inhibitors in various diseases.
  • To discuss the progress of BTK inhibitors in preclinical and clinical studies.

Main Methods:

  • X-ray crystallography to study BTK conformations with various ligands.
  • Development of reversible and covalent BTK inhibitors.
  • Preclinical testing in models of autoimmunity and oncology.
  • Clinical trials for oncology indications.

Main Results:

  • BTK inhibitors have shown efficacy in preclinical models.
  • Two BTK inhibitors have advanced to human clinical trials for oncology.
  • Ibrutinib, a BTK inhibitor, received FDA approval for mantle cell lymphoma.

Conclusions:

  • BTK inhibitors represent a promising therapeutic strategy for cancer and autoimmune diseases.
  • The unique structural features of BTK enable the development of highly selective drugs.
  • Ongoing clinical studies may expand the use of BTK inhibitors to other autoimmune conditions.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

7.1K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.5K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
15.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
64.6K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81